Linzagolix

Generic Name
Linzagolix
Brand Names
Yselty
Drug Type
Small Molecule
Chemical Formula
C22H15F3N2O7S
CAS Number
935283-04-8
Unique Ingredient Identifier
7CDW97HUEX
Background

Linzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis. It is similar to other GnRH receptor antagonists like cetrorelix, relugolix, and elagolix.
...

Indication

Linzagolix is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Associated Conditions
Moderate Uterine Fibroids, Severe Uterine Fibroids
Associated Therapies
-
Clinical Trials
Related News

Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

Phase 1
Completed
Conditions
Healthy Participants
Hepatic Impairment
Interventions
Drug: Linzagolix
First Posted Date
2019-05-23
Last Posted Date
2020-01-13
Lead Sponsor
ObsEva SA
Target Recruit Count
24
Registration Number
NCT03962049
Locations
🇺🇸

Clinical Site, Orlando, Florida, United States

Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function

Phase 1
Completed
Conditions
Renal Impairment
Healthy Participants
Interventions
Drug: Linzagolix
First Posted Date
2019-05-23
Last Posted Date
2020-03-05
Lead Sponsor
ObsEva SA
Target Recruit Count
33
Registration Number
NCT03961932
Locations
🇺🇸

Clinical Site, Saint Paul, Minnesota, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy